After a 16-year wait for the US Food and Drug Administration (FDA) to approve its lung imaging tool, Cyclopharm (ASX:CYC) is ...

All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

“Patients with mild-to-moderate COPD who have low exercise tolerance are likely to experience poor respiratory health outcomes,” the investigators concluded. “Exercise tolerance may be considered one ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

Saban Community Clinic (SCC) is excited to announce the promotion of Dr. Noble to the role of Chief Medical Officer (CMO). A ...